Baird on Regenxbio Inc. (RGNX): 'Incrementally positive on 2026 update'

Baird analyst Brian Skorney reiterated an Outperform rating and $39.00 price target on Regenxbio Inc. (NASDAQ: RGNX).

The analyst comments "Incrementally positive on 2026 update. REGENXBIO shared updated data from its RGX-202 program, noting four patients treated with the pivotal dose level of RGX-202 continue to perform well above matched natural history subjects and predicted trajectory on NSAA. The pivotal topline from this program is expected in early 2Q26, with a BLA filing anticipated in mid-2026. Pivotal sura-vec data in wAMD is expected in 4Q26 with a $100M expected in 1H26 with DR trial initiation. RGX-121 also remains on track for a Feb. 8 PDUFA date and potential PRV."

For an analyst ratings summary and ratings history on Regenxbio Inc. click here. For more ratings news on Regenxbio Inc. click here.

Shares of Regenxbio Inc. closed at $14.59 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery